title: Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
abstract: To clarify whether expression of the programmed cell death 5 (PDCD5) gene in leukemic cells is abnormal, real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) was used to examine its expression in marrow cells from leukemia patients. We found lower PDCD5 in both AML and CML marrow cells than in normal donor marrow cells. A negative correlation was found between relative levels of PDCD5 and BCR/ABL expression in all CML patients and in CML patients in the advanced phase. Treatment with the ABL tyrosine kinase inhibitor Imatinib mesylate increased PDCD5 expression in K562 and MEG-01 cells. These findings suggest that abnormal expression of PDCD5 in leukemia may be involved in the pathomechanism of AML and CML.
authors.affiliation: Institute of Hematology and People's Hospital, Peking University, 11 Xi-zhi-men South Street, Beijing 100044, China.
authors.forename: Guo-Rui
authors.initials: GR
authors.lastname: Ruan
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Qin
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Chen
authors.forename: Jin-Lan
authors.initials: JL
authors.lastname: Li
authors.forename: Xi
authors.initials: X
authors.lastname: Ma
authors.forename: Yan
authors.initials: Y
authors.lastname: Chang
authors.forename: Ya-Zhe
authors.initials: YZ
authors.lastname: Wang
authors.forename: Jia-Yu
authors.initials: JY
authors.lastname: Fu
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Liu
mesh_terms: D000328:Adult; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis* / Q000235:genetics; D001549:Benzamides; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D051017:Apoptosis Regulatory Proteins; D001549:Benzamides; D009363:Neoplasm Proteins; C117283:PDCD5 protein, human; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl